A single-arm, open-label, phase II study evaluating Neoadjuvant immunotherapy (PD-1) combined with chemotherapy for locally advanced thoracic esophageal carcinoma (EC)
Latest Information Update: 03 Jul 2024
At a glance
- Drugs Paclitaxel (Primary) ; Pembrolizumab (Primary) ; Tislelizumab (Primary)
- Indications Carcinoma; Oesophageal cancer; Thoracic disorders
- Focus Therapeutic Use
Most Recent Events
- 03 Jul 2024 New trial record
- 04 Jun 2024 Results(From Jan 11, 2021 to, Apr 25 2022, n= 42 pts) evaluating the efficacy and safety of PD-1 combined with chemotherapy as neoadjuvant therapy, presented at the 60th Annual Meeting of the American Society of Clinical Oncology